Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma

Oncology Letters

Volumn 5, Issue 3, 2013, Pages 805-812

  Zhao, Xin ^a   Zhang, Guang Bo ^a   Gan, Wen Juan ^a   Xiong, Feng ^a   Li, Zhi ^a   Zhao, Hua ^a   Zhu, Dong Ming ^a   Zhang, Bin ^a   Zhang, Xue Guang ^a   Li, De Chun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

B7 H3; Chemoresistance; Pancreatic carcinoma; ShRNA

Indexed keywords

GEMCITABINE; LYMPHOCYTE ANTIGEN; PROTEIN B7 H3; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NICK END LABELING; NONHUMAN; PANCREAS CARCINOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; WESTERN BLOTTING;

EID: 84872722908     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1118     Document Type: Article

References (26)

1. Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet 363: 1049-1057, 2004.
2. Jemal A, Murray T, Samuels A, et al: Cancer statistics, 2003. CA Cancer J Clin 53: 5-26, 2003.
3. Laheru D and Jaffee EM: Immunotherapy for pancreatic cancer-science driving clinical progress. Nat Rev Cancer 5: 459-467, 2005.
4. Ghaneh P, Costello E and Neoptolemos JP: Biology and management of pancreatic cancer. Postgrad Med J 84: 478-497, 2008.
5. Pan X, Sheng WH, Zhu QY, et al: Inhibition of pancreatic carcinoma growth by adenovirus-mediated human Interleukin-24 expression in animal model. Cancer Biother Radiopharm 23: 425-434, 2008.
6. Chapoval AI, Ni J, Lau JS, et al: B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2: 269-274, 2001.
7. Sun M, Richards S, Prasad DV, et al: Characterization of mouse and human B7-H3 genes. J Immunol 168: 6294-6297, 2002.
8. Steinberger P, Majdic O, Derdak SV, et al: Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol 172: 2352-2359, 2004.
9. Zhang GB, Zhou H, Chen YJ, et al: Characterization and application of two novel monoclonal antibodies against 2IgB7-H3: expression analysis of 2IgB7-H3 on dendritic cells and tumor cells. Tissue Antigens 66: 83-92, 2005.
10. Arigami T, Narita N, Mizuno R, et al: B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann Surg 252: 1044-1051, 2010.
11. Crispen PL, Sheinin Y, Roth TJ, et al: Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 14: 5150-5157, 2008.
12. Boorjian SA, Sheinin Y, Crispen PL, et al: T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res 14: 4800-4808, 2008.
13. Zang X, Thompson RH, Al-Ahmadie HA, et al: B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA 104: 19458-19463, 2007.
14. Sun Y, Wang Y, Zhao J, et al: B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 53: 143-151, 2006.
15. Yamato I, Sho M, Nomi T, et al: Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer 101: 1709-1716, 2009.
16. Loos M, Hedderich DM, Ottenhausen M, et al: Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer 26: 463, 2009.
17. Roth TJ, Sheinin Y, Lohse CM, et al: B7-h3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 67: 7893-7900, 2007.
18. Gregorio A, Corrias MV, Castriconi R, et al: Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7-H3 surface molecule. Histopathology 53: 73-80, 2008.
19. Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8: 61-70, 2008.
20. Li F, Ambrosini G, Chu EY, et al: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584, 1998.
21. Hunter AM, LaCasse EC and Korneluk RG: The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12: 1543-1568, 2007.
22. Schimmer AD: Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 64: 7183-7190, 2004.
23. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997.
24. Tamm I, Wang Y, Sausville E, et al: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58: 5315-5320, 1998.
25. Yoon DH, Shin JS, Jin DH, et al: The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2. Anticancer Res 32: 1681-1618, 2012.
26. Hung CS, Lin SF, Liu HH, et al: Survivin-mediated therapeutic efficacy of gemcitabine through glucose-regulated protein 78 in hepatocellular carcinoma. Ann Surg Oncol 19: 2744-2752, 2012.